I NTRACRANIAL hemorrhage is the most dreaded complication of hemophilia and is now the leading cause of death in this disease2 ,1~ Silverstein, lz reviewing the world literature to 1960, reported a mortality of 71%. In his series, eight of 30 patients were treated with surgical intervention 11 times with only two survivals. With recent advances la,l~ which allow the production of low volume, extremely potent concentrates of Factor viii (anti-hemophiliac globulin, or AHG), the outlook for survival and successful surgical intervention in classical hemophilia is greatly improved. The following case report describes the surgical management of a subdural hematoma in a hemophiliac patient using the most widely available Factor viii concentrate, cryoprecipitate, ~a to correct the clotting defect. The successful outcome of this case testifies that intracranial surgery may be safely performed in the hemophiliac patient.
Case Report
This 22-year-old university student, with recognized classical hemophilia, was admitted to Victoria Hospital on May 19, 1967 , because of a seizure that had followed 2 days of severe bifrontal headache. There was no history of recent injury. The diagnosis of classical hemophilia had been made in infancy following 21 days of bleeding from a minor gum injury. Since then, the patient had experienced intermittent prolonged external bleeding from minor injury, soft tissue hemorrhages, mild hemarthroses, and an episode of gastrointestinal bleeding. All of these bleeding episodes had been controlled with small amounts of fresh frozen plasma.
Examination. Examination revealed only neck stiffness and early papilledema. Skull x-rays were normal. Echoencephalography
Received for publication February 6, 1968. showed a midline shift of 4 mm to the right. The partial thromboplastin time (PTT) was 83 sec (normal, 33-45 sec) with a Factor 8 level of 6% (normal, 50-200%). Four units of cryoprecipitate were given with no improvement in his symptoms. That evening a left frontal adversive seizure occurred, and the patient was placed on Dilantin and Decadron. A RISA brain scan revealed an area of increased uptake overlying the left cerebral convexity, consistent with that of a subdural hematoma. Surgical treatment had to be delayed until sufficient cryoprecipitate for operation and the first 7 postoperative days could be accumulated. During this forced delay, the patient's neurological status steadily deteriorated. By May 21, he was dysphasic and had a mild right facial palsy. There were periods of marked confusion, restlessness, and intermittent focal seizures involving the right face and shoulder girdle musculature. The headache remained severe and uncontrollable.
On May 23, left carotid angiography was performed 2 hours after the intravenous administration of 4 units of cryoprecipitate, which had elevated the Factor viii level to 30%. The angiogram confirmed the presence of a moderate-sized subdural hematoma on the left. There was no abnormal bleeding from this procedure, but in the evening an episode of status epilepticus required 300 mg of Sodium Luminal and 4 mg of Valium intravenously for control. The following day the patient received an additional 6 units of cryoprecipitate.
Operation. On May 25, 6 days after admission, the patient was prepared for operation with 10 units of cryoprecipitate, which elevated the Factor vnI level to 51%, and reduced the PTT to 40 sec. The partially liquifled hematoma was evacuated through two burr holes placed in the frontal and parietal regions. There was no unusual bleeding, and 524 the technique differed in no way from that in a nonhemophiliac individual.
Postoperative Course. Recovery was uneventful. The PTT was maintained at a normal level with large amounts of cryoprecipitate. In total, 126 units were used, of which 102 units were administered in the postoperative period. This is equivalent to 31.5 litres of fresh frozen plasma. Initially, 6 units of cryoprecipitate were used every 6 hours, and on the second postoperative day a graduated reduction of the dosage was begun. No cryoprecipitate was given after the 6th postoperative day, and by the 10th day the PTT was once again 80 sec. The wounds healed well, and the sutures were removed on the 8th postoperative day without incident.
A postoperative angiogram performed on June 8 after the administration of Connaught Factor viii concentrate showed that there was no longer any evidence of the subdural hematoma. At the time of discharge 2 days later, the patient showed great improvement from his preoperative state. He was free of headache and had had no seizures. The profound dysphasia had regressed to the point of minimal expressive difficulties. He is attending his university again and remains well.
Discussion
Classical hemophilia is a sex-linked recessive disorder of blood coagulation due to a primary Factor viii deficiency that occurs in Caucasians with a frequency of 2 to 3 per 100,000. Minor and Taylor 1 demonstrated in 1947 the presence of Factor viii in normal blood and its absence or deficiency in classical hemophilia. Biggs, 1 in 1955, developed a technique for the assay of Factor viii and demonstrated that there was a close correlation between the clinical severity of hemophilia and the level of Factor viii in the blood. The clinical and laboratory assessment of the severity of the disease 4 is as follows: patients with severe hemophilia bleed spontaneously with Factor viii levels less than 1%; moderate hemophiliacs, as in the case presented here, bleed from minor trauma with Factor viii levels of 1-10%; mild hemophiliacs bleed only after more severe trauma with Factor viii levels greater than 10%. Biggs also demonstrated that a total correction of the hemostatic defect in hemophilia was possible if Factor viii was supplied in amounts adequalc to produce normal or near nornla[ levels (50-200%). The modern management of bleeding episodes in a hemophiliac patient is dependent on this fundamental work.
Spontaneous bleeding in hemophilia is controlled with a Factor viii level of 10-15 %. Traumatic bleeding requires a level of at least 30%. With whole plasma it is not possible to achieve Factor viii levels above 25% or maintain them above 10% for more than 2 to 3 daysY To achieve the necessary high levels, efforts in the past decade have been directed toward the development of increasingly potent preparations of Factor viii, ranging from fresh frozen plasma to concentrated preparations of human and animal Factor viii. This work has culminated in the production of various highly potent, human concentrates of Factor viii. The most widely used and available of these is cryoprecipitate, produced by the isolation of Factor viii in the cold insoluble precipitate of fresh frozen plasma. This technique, which represents a great advance in the care of the hemophiliac, was described by Pool and Shannon in 1965.1'~ Cryoprecipitate overcomes many of the disadvantages of earlier preparations. -~, 19 From a pint of fresh whole blood, the yield of Factor viii is only 3 ml. This is reconstituted with normal saline to a total volume of 13 ml, which represents 1 unit of cryoprecipitate. The low volume avoids the problem of circulatory overload when enormous quantities of Factor viii are required, as in this case, where Factor viii equivalent of 7 litres of fresh frozen plasma was used in the first 24 hours following surgery. Cryoprecipitate is a human blood product, thus avoiding the problem of antigenicity encountered with animal concentrates. Cryoprecipitate is also relatively simple and inexpensive to prepare. It can be produced in a hospital blood bank equipped with storage facilities at --60~ refrigeration, a refrigerated centrifuge, plastic dual pack collection systems, and a ready supply of fresh whole blood. As it can be stored in the frozen state in low volume, cryoprecipitate can be prepared in anticipation of need, and reconstituted as required. Pool and Shannon 13 have shown that it can be frozen and stored for 6 months without significant loss of potency.
Recent reports 9,16 state that intracranial hemorrhage has become the most common cause of death in hemophilia. Kerr ~ emphasized that with the increasing life expectancy of the hemophiliac patient because of better control of bleeding at other sites, intracranial hemorrhage was likely to play an increasingly major role in the production of morbidity and mortality in these individuals. SiN verstein, ~r in his exhaustive review of the world literature to 1950, reported an overall mortality from intracranial hemorrhage of 71%. Kerr 9 in a less complete review reports a mortality of 33%.
In addition to our case, only 19 attempts at surgical treatment of intracranial hemorrhage in hemophilia have been reported ( Table 1 ). There were 10 survivals, eight occurring in the nine cases reported since 1960. Jamieson reported the first successful intracranial procedure in a hemophiliac in 1954. There are only seven previously reported cases of subdural hematoma alone, treated surgically. Five of the seven survived. All three of the most recent cases have survived with the use of cryoprecipitate. The report of Prentice, et al., 1~ in 1967 appears to be the first use of cryoprecipitate for intracranial surgery in hemophilia. Moody and Mullan have recently removed successfully a posterior fossa subdural hematoma in a classical hemophiliac, with the use of large amounts of cryoprecipitate2 ~ Matson TM has also operated successfully on two hemophiliac patients making use of cryoprecipitate.
All but the most recent cases have been characterized by prolonged and complicated postoperative courses. Kerr 9 reports a typical case without the benefit of the newer preparations. This 6-year-old, severe hemophiliac developed a subdural hematoma following a minor injury. Unsatisfactory control of the coagulation defect was obtained using fresh frozen plasma prior to surgery. Initial evacuation through burr holes was inadequate, and repeat evacuation through a craniotomy was necessary. The boy survived after a stormy postoperative course characterized by excessive and prolonged bleeding at the operative site, seizures, wound infection, and 7-month hospitalization. The first instance of a safe evacuation of subdural hematoma in a hemophiliac using simple burr holes and without a complicated postoperative course was reported by Davies, et al., 4 
in 1966Y
In their case, the clotting defect was successfully corrected using an older, high volume Factor viii concentrate.
It is interesting that known trauma was associated with only 45% of Silverstein's cases and 26% of Kerr's series. There was no history of trauma in our case. The site of intracranial hemorrhage has held an important bearing on the suitability of the case for surgery and the prognosis. In 45 % of Silverstein's cases, the bleeding occurred in the epidural or subdural spaces and the only survivors following surgery until 1960 had hematomas in these spaces. In 1962, Singer and Schneider 2~ reported the first successful removal of an intracerebral clot in a hemophiliac.
Silverstein considered surgical intervention warranted, as a last resort, if the following criteria were fulfilled: 1) progressive neurological deterioration in spite of the best possible conservative management, 2) adequate hematological control, and 3) the site of bleeding was known to be either the epidural or subdural space. These restrictions were based on the fact that, in 1960, truly adequate means of controlling the clotting defect in a severe hemophiliac patient were not available.
As late as 1966, Fessey and MeynelP recommended that no diagnostic or therapeutic procedures, even including lumbar puncture, should be performed on hemophiliac patients because of the inherent danger of excessive bleeding. Rather, empirical treatment with Factor viii supplements, where a presumptive diagnosis of intracranial hemorrhage was made, was advised. Diagnosis was based on a history of trauma followed by neurological deterioration, or on the presence of headache of greater than 12 hours' duration. Unfortunately, one of their five cases died of a subdural hematoma, demonstrated at autopsy.
In the same year, Davies, et a l., 4 reported their series of five cases in which aggressive investigation and surgical intervention, including craniotomy, was undertaken with the protection of some Factor viii replacement. They used an older, high-volume low-potency Factor viii concentrate available in Britain since 1958, to restore temporarily a near normal clotting mechanism. They reiterated Silverstein's original criteria The recent development of low-w~lume high-potency Factor viii concentrates, of which cryoprecipitate is the most widely used, makes the approach to the management of intracranial hemorrhage in hemophilia, as outlined by Davies, et al., even more applicable. Our case and others reported recently 3,11,'~ illustrate that presumptive intracranial hemorrhage in hemophilia can be fully investigated and adequately treated if control of the clotting defect is achieved. With the advent of cryoprecipitate, truly adequate control of the clotting defect is possible for the first time. It is now unreasonable, in view of this development, to live in fear of intracranial surgery in hemophilia. It is to be expected that in the future the present high mortality will fall.
Summary
We have reported the successful surgical management of a subdural hematoma in a case of classical hemophilia utilizing recent advances in hematology. The present availability of cryoprecipitate makes the temporary correction of the hemostatic defect in classical hemophilia possible, and allows full investigation and surgical treatment of intracranial or other hemorrhage, 1~ as in a normal person. A timid approach to surgery in the hemophiliac patient is no longer justified. We have reviewed other reports of attempts to treat intracranial hemorrhage in hemophilia.
